Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM12470 vs Regular Human Insulin in Healthy Subjects
NCT03330327Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Aug 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HM12470 in diabetes mellitus (DM), sponsored by Hanmi Pharmaceutical. Primary endpoint: Blood glucose assessment at 1 month. Started Mar 2015; status: completed.
02
Drugs
HM12470
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03330327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330327.